Insulin acutely inhibits intestinal lipoprotein secretion in humans, in part by suppressing plasma free fatty acids

Running title: Insulin and intestinal lipoprotein secretion

Mirjana Pavlic*, MD, Changting Xiao*, PhD, Linda Szeto, MSc, Bruce W. Patterson, PhD, and Gary F. Lewis, MD

* These authors (MP and CX) contributed equally to this manuscript

From Departments of Medicine and Physiology, Division of Endocrinology and Metabolism, University of Toronto, Toronto, Canada (M.P., C.X., L.S., G.F.L.) and Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA (B.W.P.)

Correspondence to:
Dr. Gary F. Lewis
Email: gary.lewis@uhn.on.ca

Additional information for this article can be found in an online appendix at http://diabetes.diabetesjournals.org

Submitted 31 August 2009 and accepted 11 December 2009.

This is an uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association, publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes in print and online at http://diabetes.diabetesjournals.org.
Objective: Intestinal lipoprotein production has recently been shown to be increased in insulin resistance, but it is not known whether it is regulated by insulin in humans. Here, we investigated the effect of acute hyperinsulinemia on intestinal (and hepatic) lipoprotein production in 6 healthy men, in the presence and absence of concomitant suppression of plasma free fatty acids (FFAs).

Research design and methods: Each subject underwent the following 3 lipoprotein turnover studies, in random order, 4 to 6 weeks apart: 1. INS study, insulin/glucose infusion (euglycemic-hyperinsulinemic clamp) to induce hyperinsulinemia; 2. INS+IH study, insulin/glucose infusion plus Intralipid and heparin infusion to prevent the insulin-induced suppression of plasma FFAs; and 3. SAL study, saline control.

Results: ‘VLDL1’ and ‘VLDL2’-apoB48 and -apoB100 production rates (PR) were suppressed by 47 to 62% by insulin, with no change in clearance. When the decline in FFAs was prevented by concomitant infusion of Intralipid and heparin (INS+IH), PR of ‘VLDL1’ and ‘VLDL2’-apoB48 and -apoB100 were intermediate between INS and SAL.

Conclusions: This is the first demonstration in humans that intestinal apoB48-containing lipoprotein production is acutely suppressed by insulin, which may involve insulin’s direct effects and insulin mediated suppression of circulating FFAs.
Dyslipidemia is a well recognized feature of insulin resistance and type 2 diabetes and is a common risk factor for atherosclerotic cardiovascular disease. Hypertriglyceridemia, low plasma concentrations of HDL and qualitative changes in LDL and profile comprise the typical dyslipidemia, which is felt to play an important but not exclusive role in accelerated atherosclerosis of affected individuals (1;2). Overproduction of large, triglyceride-rich, apoB100-containing, hepatic VLDL1 particles has been well documented in animal models and in humans with insulin resistance and type 2 diabetes and contributes to the dyslipidemia (3;4). In addition, postprandial hyperlipidemia and elevated plasma concentrations of intestinal apoB48-containing particles have been demonstrated in insulin resistant states (5-9). We and others have recently shown that insulin resistant animal models and humans have overproduction of intestinal, apoB48-containing lipoproteins (10-12). Whereas numerous factors are known to regulate hepatic lipoprotein particle overproduction, less is known about factors that regulate intestinal lipoprotein production in insulin resistant conditions.

We have recently shown that acute elevation of plasma FFAs stimulates not only hepatic (13) but also intestinally derived apoB48-containing lipoprotein particles in fed humans (14), demonstrating that at least one of the factors involved in the regulation of hepatic lipoprotein production also regulates intestinal lipoprotein particle production. Insulin has been shown both in vitro (9;15;16) and in vivo in animals and humans (13;17-22) to acutely suppress hepatic apoB100-containing lipoprotein particle production. This acute suppressive effect on VLDL in fasting individuals has been shown to be in part dependent on the FFA suppression induced by acute hyperinsulinemia in vivo (13;21), and is due predominantly to suppression of the VLDL1 fraction with no (22) or an opposite effect on VLDL2 (17). Insulin resistant hyperinsulinemic, obese humans and those with type 2 diabetes are resistant to the acute inhibitory effect of insulin on VLDL production (18;20) as are primary cultured hepatocytes derived from insulin resistant rats (23). At least part of the effect of insulin is direct, occurring by co- and posttranslational mechanisms through increasing posttranslational protein degradation (24). Incubation of human fetal small intestinal cells with insulin has also been shown to reduce chylomicron secretion (25). Recent studies showed that intestinal lipoprotein production in chow-fed hamsters is responsive to the acute inhibitory effect of insulin, whereas enterocytes derived from insulin resistant, fructose-fed hamsters are resistant to this acute suppressive effect of insulin through an aberrant intestinal insulin signaling cascade (26). The responsiveness of intestinal lipoprotein secretion to acute hyperinsulinemia has not previously been examined in humans.

In the present study we used the euglycemic, hyperinsulinemic clamp technique to examine the effects of acute hyperinsulinemia on ‘VLDL1’ and ‘VLDL2’ intestinal (apoB48) and hepatic (apoB100) lipoprotein production in six healthy men in a constant fed state. We found that insulin infusion suppresses both ‘VLDL1’ and ‘VLDL2’ apoB48 and apoB100 concentrations, due to suppression of ‘VLDL1’ lipoprotein secretion, with consequently less ‘VLDL2’
being formed from ‘VLDL1’. When Intralipid and heparin were co-infused to prevent insulin-induced suppression of plasma FFAs, production rates of these lipoproteins were still suppressed, although to a lesser extent. These results indicate that insulin directly suppresses both intestinal and hepatic lipoprotein production in humans.

MATERIALS AND METHODS

Subjects: The demographic characteristics and fasting biochemical profiles of the six healthy, normolipidemic, male participants in this study are outlined in Table 1. None of the participants had any previous history of cardiovascular disease, gastrointestinal or systemic illness, or surgical intervention within six months prior to the studies. No subject was taking medications and all had normal oral glucose tolerance tests performed immediately prior to enrollment in the study. The Research Ethics Board of the University Health Network, University of Toronto, approved the study and all subjects gave written informed consent prior to their participation.

Experimental Protocol for lipoprotein kinetic studies: Each subject underwent three separate lipoprotein kinetic studies as described below, in random order, 4 to 6 weeks apart (Figure 1A). In each study, following an overnight fast (no food ingested after 5pm the night before the kinetic study), an iv catheter was inserted into a superficial vein in each forearm, one for infusion and one for blood sampling. Kinetic studies were performed in the constant fed state because apoB48 levels are too low in the fasted state to accurately assess isotopic enrichments for calculation of kinetic parameters. To achieve a constant fed state the subjects ingested aliquots of a liquid food supplement (Hormel Great Shake Plus™, Hormel Health Labs, GA, USA; total fat 10% by weight, saturated fat 1.5%, trans fat 0%, monounsaturated fat 2.6%, polyunsaturated fat 5.6%, cholesterol 0%; 49% calories from fat, 38% from carbohydrates, 13% from proteins) every hour for the first 3 hours starting at 4am, each hourly aliquot equivalent to 1/16th of their total daily caloric needs. After the first 3 hours (after 7am), the subjects ingested the same formula every half hour for the remainder of the study, each aliquot equivalent of 1/34th of their daily caloric intake. The Harris Benedict Equation was used to estimate the total daily energy requirement for each subject.

In one study (INS), circulating insulin levels were increased through iv infusion of insulin (40mU/m².min, Humulin R, Eli Lilly Canada, Toronto, ON, Canada), starting at 7am. Blood glucose was assessed at the bedside using a Beckman Glucose Analyser (Beckman Coulter Canada, Mississauga, Canada) every 5 to 10 min and a 20% dextrose solution at varied rate to maintain the blood glucose in the 5 to 6 mmol/L range. In another study (SAL), saline was infused at 65 mL/hr. Since insulin suppresses circulating FFAs, a second control study (INS+IH) was performed, where Intralipid (20% solution at 15mL/hr) and heparin (250 U/hr) were co-infused with insulin and dextrose to prevent a decrease in circulating FFAs. The Intralipid plus heparin infusion protocol has been routinely used to elevate circulating FFAs (14;27).

Six hours after starting the liquid formula ingestion and three hours after starting the SAL or INS or INS+IH infusions (i.e. 10am), all subjects received a primed, constant infusion (10 µmol/kg bolus followed by 10 µmol/kg.hr for 10
Insulin and intestinal lipoprotein secretion

5 hrs) of L-[5,5,5-2H3]-leucine (D3-leucine, 98%, Cambridge Isotope Laboratories, Andover, MA, USA) for assessment of production and clearance rates of the lipoprotein particles as previously described (28). After the start of the D3-leucine infusion, blood samples were collected at 1, 2, 3, 5, 7, 9 and 10 hr for isolation of lipoproteins. Blood samples for insulin, FFA and TG analysis were collected as previously described (14).

Laboratory Methods: Plasma was separated from blood samples within 2 hrs and subjected to cumulative flotation gradient ultracentrifugation to isolate VLDL1 and VLDL2 fractions (29;30). Briefly, plasma was adjusted to d=1.10 g/mL with NaCl. A discontinuous density gradient consisting of 4mL of d=1.10g/mL of plasma, 3mL of d=1.063g/mL, 3mL of d=1.019g/mL and 2.8 mL of d=1.006g/mL NaCl solution was created. The Ti40 SW rotor (Beckman, Palo Alto, CA) was subjected to centrifugation at 40,000 rpm at 4ºC. Consecutive runs were performed to separate fractions that correspond to chylomicron (Sf>400, 38min), VLDL1 (Sf 60-400, 3hr 28min) and VLDL2 (Sf 20-60, 17hr). After each step 1mL of the gradient containing specific lipoprotein fraction was aspirated and 1mL of d=1.006g/mL NaCl solution was added to refill the tubes before the next run.

VLDL fractions with approximately 1000µg protein were delipidated and separated by preparative 3.3% SDS-PAGE. Gel bands corresponding to apoB48 and apoB100 were excised. ApoB48 and apoB100 gel slices were hydrolyzed and derivatized to allow for the determination of plasma leucine isotopic enrichment as described (11). Briefly, samples were heated at 110ºC with 6N HCl and norleucine as internal standard for 24h and dried under vacuum before being derivatized with 100 µL mixture (1:1) of acetonitrile: N-tert-butylimidethyl-N-methyltrifluoracetamide (Sigma-Aldrich). Plasma free amino acids were recovered from 0.25mL plasma after precipitation of proteins with 1.8mL acetone and extraction of the aqueous phase with hexane (31). The aqueous phase was dried under vacuum and amino acids derivatized and enrichments determined as described above. Derivatized samples were analyzed by electron impact ionization GC/MS (Agilent 5975/6890N, Agilent Technologies Canada INC, Mississauga, ON, Canada) using helium as the carrier gas (32). Selective ion monitoring at m/z =200 and 203 was performed, and tracer-to-tracee ratios calculated from isotopic ratios for each sample according to the formula derived by Cobelli et al (33).

Triglycerides were measured using an enzymatic colorimetric kit (Roche Diagnostics, Mannheim, Germany). This assay eliminates free glycerol in a preliminary reaction prior to enzymatic hydrolysis of TG and determination of the liberated glycerol, therefore presence of free glycerol in Intralipid does not affect TG assay results. Cholesterol was determined using the CHOD-PAP enzymatic colorimetric kit (Roche Diagnostics). FFAs were determined with the NEFA colorimetric method (Wako Industrials, Osaka, Japan). Plasma insulin concentrations were assayed by radioimmunoassay using a human specific insulin kit (Linco Research, St Louis, MO, USA). ApoB100 was separated by 3-8% SDS-PAGE and quantified using an LDL apoB100 standard as previously described (34). ApoB48 mass was determined using a human apoB48 ELISA kit with intra-assay CV of 3.5% and inter-assay CV of 5.7% (Shibayagi, Japan).
Calculation of lipoprotein production and clearance rates by compartmental modeling: Stable isotope enrichment curves for apoB48 and apoB100 were fitted to a multi-compartmental model using SAAM II software (version 1.2, University of Washington, Seattle, WA). Both apoB48 and apoB100 were modeled using the same structural model (Figure 2). Incorporation of leucine into VLDL1 and VLDL2 occurred via the delay compartment 2. Individual enrichment (tracer to tracee ratios) and apoB masses were used to derive kinetic rate constants which were independent for the two subsystems. Plasma leucine enrichment was used as a forcing function. Fractional catabolic rate (FCR) of VLDL1 was the sum of the conversion from VLDL1 to VLDL2 and direct loss from the VLDL1 compartment. All of the parameters were allowed to adjust except the delay which was set to 0.5hr as used by others (22). Production rates (PR) were calculated using the FCR of VLDL1 and VLDL2 apoB48 or VLDL1 and VLDL2 apoB100 multiplied by pool size measured over the 10 hrs of the kinetic study, where pool size = average plasma concentration (mg/L) between 1 and 10 hr of the kinetic study x plasma volume /kg body weight (estimated as 0.045 liter/kg).

Statistics: Results are presented as mean ± SEM. Mean values of the parameters of interest and statistical comparison between studies were calculated during the 10 hr kinetic study (i.e. from approximately 10am to 8pm, the time period during which deuterated leucine was infused). Repeated measures ANOVA was used to compare the kinetic experiments and other results between the three groups, followed by a pair-wise comparison post hoc (Tukey’s and Tamhane’s) to examine the differences between the groups. All analyses were performed with the SPSS version 15. For all of the analyses, a p value < 0.05 was considered significant.

RESULTS
Plasma insulin, FFA and TG concentrations: By design, insulin infusion increased plasma insulin levels by >4-fold as compared with SAL (INS 348±34 and INS+IH 333±32 pmol/L vs SAL 64.8±19.9 pmol/L; p<0.0001) while insulin concentrations were similar in INS and INS+IH (p=ns). As a result of the hyperinsulinemia, plasma FFA concentrations in INS were suppressed by >2-fold as compared with SAL, which was prevented by Intralipid plus heparin infusion (INS 0.12±0.01 and INS+IH 0.29±0.03 mmol/L vs SAL 0.25±0.05 mmol/L, p=0.0001) (Figure 1C; Table 2). Plasma TG in all treatments increased in response to feeding and remained constant throughout the 10-hr kinetics study. Insulin infusion resulted in decreased levels of circulating TG as compared with saline infusion (p <0.0001 value INS vs SAL), while Intralipid plus heparin co-infusion prevented the insulin induced decrease in plasma TG and caused additional rise in plasma TG concentration when compared to saline infusion (p<0.0001 INS+IH vs SAL) (Figure 1B; Table 2).

Effect of acute hyperinsulinemia, with and without decreased plasma FFAs, on VLDL1 and VLDL2 apoB48 and apoB100 concentrations: VLDL1 and VLDL2 apoB48 concentrations rose after the start of ingestion of the high fat, liquid formula (at 4am) and then remained elevated but constant throughout the 10-hr kinetic study (from 10am to 8pm). The overall difference for VLDL1 and VLDL2 apoB48 concentrations between the three studies was significant at p<0.0001 and p=0.036 respectively. Post-hoc analysis
revealed that insulin infusion in INS was associated with a significant reduction in both VLDL1 and VLDL2 apoB48 concentrations compared to SAL and INS+IH, which were not different from one another (Figure 3A and C) (VLDL1 apoB48: INS 0.90±0.27 vs SAL 1.83±0.19 vs INS+IH 1.63±0.15 mg/L; VLDL2 apoB48: INS 1.12±0.33 vs SAL 1.58±0.11 vs INS+IH 1.56±0.15 mg/L) (Table 2).

Similarly, both VLDL1 and VLDL2 apoB100 concentrations differed (p<0.0001) between the three studies over the time course of the kinetic study. Again, with post-hoc comparison INS was shown to be significantly different from SAL and INS+IH, while no difference was observed between SAL and INS+IH. (Figure 3B and D) (VLDL1 apoB100: INS 0.70±0.16 vs SAL 1.76±0.42 vs INS+IH 1.97±0.51 mg/dL; VLDL2 apoB100: INS 0.94±0.31 vs SAL 1.96±0.56 vs INS+IH 1.90±0.47 mg/dL) (Table 2).

Effect of acute hyperinsulinemia, with and without decreased plasma FFAs, on VLDL1 and VLDL2 apoB48 and B100 fractional catabolic rates and production rates: To elucidate the mechanism of hyperinsulinemia associated reductions in both VLDL1 and VLDL2 apoB48 and B100 concentrations, we further examined whether the reductions was due to increased fractional catabolic rates (FCR) or decreased production rates (PR). FCR did not differ significantly between the three studies for either apoB48 or apoB100 in either of the two VLDL fractions (Table 2; Figure 4A-D) (individual kinetics parameters are shown in supplementary Table which is available at http://diabetesjournals.org). Instead, the decreased plasma concentrations were due to reduced production, indicated by lower PR of apoB48 and apoB100 in VLDL1 (p=0.009 for apoB48 and P=0.029 for apoB100 INS vs SAL) and apoB48 in VLDL2 (P=0.01 vs SAL) and a trend towards a reduction in VLDL2 apoB100 (p=0.067 vs SAL) (Table 2; Figure 4E-H). VLDL1 and 2 apoB48 and apoB100 PR in INS+IH were in all cases intermediate between INS and SAL, but were not significantly different from the other two studies. A further breakdown of the source of production indicated that the production of apoB48 in the VLDL2 fraction was entirely via VLDL1 in all treatment groups. Insulin-induced suppression of VLDL2 apoB48 concentration was therefore entirely attributable to its reduced production via VLDL1 (P<0.05 INS vs SAL). In contrast, a significant proportion of the production of VLDL2 apoB100 was direct (ie not via VLDL1), which was similar between treatments. Production of VLDL2 apoB100 via VLDL1 was significantly suppressed by insulin (INS vs SAL, P<0.05), whereas direct VLDL2 apoB100 production was not suppressed by insulin.

DISCUSSION

In this study we investigated the effect of acute hyperinsulinemia on intestinal and hepatic lipoprotein production in humans in a constant fed state, in the presence and absence of insulin-induced suppression of plasma FFAs. We have previously shown that insulin acutely suppresses TRL total apoB (mainly apoB100) triglyceride and particle production, at least partly due to hyperinsulinemia-induced suppression of plasma FFAs (13). We have also recently shown that short-term elevation of plasma FFAs stimulates hepatic apoB100-containing lipoprotein production, in both the fasted (13) and fed (14) states, as well as intestinal apoB48-containing lipoprotein production in the fed state.
Insulin and intestinal lipoprotein secretion

(14), suggesting that similar factors involved in the regulation of hepatic lipoprotein production also regulate intestinal lipoprotein production. Here, in addition to confirming our previous findings that insulin acutely suppresses hepatic apoB100-containing lipoprotein production, we also demonstrated for the first time in humans that insulin acutely suppresses intestinal apoB48-containing lipoprotein production, which could only be partly accounted for by insulin-mediated suppression of plasma FFAs and may involve mechanisms independent of suppression of plasma FFAs.

We examined apoB48 and apoB100 lipoprotein metabolism in large ‘VLDL1’ and small ‘VLDL2’ subclasses of TRL, separately. VLDL1 and VLDL2 were isolated by cumulative flotation gradient ultracentrifugation and the chylomicron fraction was removed before the remaining two fractions were separated. The chylomicron fraction contains relatively few, very large, TRL particles, with considerably less apoB48 and B100 content compared to VLDL1 and VLDL2 fractions (35;36). In fact, in our study the apoB48 content in the chylomicron fraction was too low to be utilized for accurate quantification of stable isotope enrichment and kinetic modeling. We therefore limited our kinetic studies to the VLDL1 and VLDL2 fractions. A novel finding in our study, besides demonstrating that insulin acutely suppresses lipoprotein production of both the hepatic and intestinal sources, was that both VLDL1 and VLDL2 fractions responded to insulin in a qualitatively similar fashion. Several previous studies have suggested that these two fractions might possess distinct kinetic properties. Adiels et al. reported that insulin acutely suppresses VLDL1 apoB secretion while stimulating VLDL2 apoB secretion, demonstrating an inverse response between VLDL1 and VLDL2 to insulin (17). Malmstrom et al. showed a decrease in VLDL1 apoB production with insulin infusion, similar to the findings of the present study, while no net response to insulin was noted in the VLDL2 fraction (22). One obvious difference between our studies and those of Adiels et al (17) and Malmstrom et al (22) is that our studies were performed in the fed rather than the fasted state, with ongoing absorption of luminal fatty acids. Whether this factor accounts for the difference in insulin’s effects on VLDL2 apoB100 production remains to be determined. If direct loss of VLDL1 apoB48 and B100 is minimal and the majority of VLDL1 is converted to VLDL2, as was the case in the current study, an intervention such as insulin infusion that suppresses VLDL1 apoB production would subsequently lead to reduced production of VLDL2 apoB from VLDL1. Our study therefore is in agreement with the studies of Malmstrom et al (22), with extended information to apoB48 production. The dominant effect of acute hyperinsulinemia is to suppress hepatic and intestinal production of large, VLDL1-density fraction particle production, whereas the reduction in VLDL2 apoB48 and B100 in response to acute hyperinsulinemia was due to the reduction in production via VLDL1 apoB48 and B100 but not their direct production. This finding would suggest similar mechanism of action in hepatocytes and intestinal enterocytes.

Although there was no significant detectable effect of the three experimental conditions on the FCR of VLDL1 and 2 apoB48 and apoB100, we cannot definitively exclude an effect of these interventions on particle clearance.
In fact both heparin and insulin have been well described to stimulate lipase activity (37), which would be anticipated to enhance particle clearance. Using a constant infusion of an endogenous tracer, FCR is measured as replacement of unlabeled VLDL with the endogenous tracer, i.e. the appearance but not the disappearance of the tracer. Although there might be a transient increase in the initial FCR immediately after Intralipid plus heparin infusion, kinetics was measured in our study in a newly established steady state after 3 hours of Intralipid plus heparin infusion. In our previous studies that examined the effect of insulin on VLDL production in humans using a semiquantitative radiolabeling technique (13;18;19) we noted a rapid decline in VLDL pool size after the infusion of insulin, intralipid and heparin, and this was presumably contributed to by stimulation of particle clearance (in addition to suppression of production), although the kinetics during the non-steady state initial 3 hour window could not be assessed using that experimental method. However after approximately 3 hours a new steady state was established, which was characterized predominantly by suppression of production. Therefore it is possible that stimulation of TRL clearance by heparin and insulin are most marked shortly after initial administration of insulin and/or heparin. If there were an initial increase in apoB FCR in the present study this may not have been detectable since the kinetics study was started 3 hours after insulin and/or heparin infusions began, in order to allow a new steady state to occur. A second possibility is the fact that our subjects were studied in the constant fed state, as opposed to the majority of previous studies that have used similar techniques in humans.

Perhaps the constant influx of lipid in some way masks an effect of heparin and insulin on particle clearance. A third theoretical possibility that could explain the absence of detectable effect on FCR is that accumulation of synthetic intralipid TRL particles may have impaired the clearance of endogenously-synthesized apoB-containing TRL particles (38;39), thereby neutralizing any theoretical increase in clearance by insulin and/or intralipid.

The mechanism by which insulin suppresses lipoprotein production is not clear. Insulin decreases FFA flux to the liver by its antilipolytic effect in adipose and other extrahepatic tissues (40), thereby indirectly suppressing VLDL biosynthesis and hepatic lipoprotein production in previous studies (13), and intestinal lipoprotein production as shown in the present study. However, suppression of hepatic lipoprotein production was not completely abrogated by preventing the insulin-mediated suppression of FFAs, thus when Intralipid was co-infused with insulin, production rates of intestinal and hepatic lipoprotein particles tended to be intermediate between the insulin and saline experiments, although not significantly different from either study. We speculate, therefore that the effect of insulin on lipoprotein production is not fully attributed to its antilipolytic and FFA-mediated effects and mechanisms independent of suppression of plasma FFAs are also involved, as we have previously demonstrated for hepatic lipoprotein production (13). Previous studies suggest that insulin regulates hepatic lipoprotein production at a co- or posttranslational level, since acute hyperinsulinemia does not affect apoB mRNA levels (15;41;42), although it is also noted that direct evidence that
insulin promotes apoB degradation in humans is currently not available and is still controversial in animal models. For instance, apoB secretion is increased in mice with complete deficiency of liver insulin receptor (43) but is decreased in mice with very low levels of liver insulin receptor (44). Insulin may mediate VLDL formation in the liver through regulation of the insulin signaling cascade (45-47) and through upregulation of genes responsible for shifting TG and FFA from VLDL formation into the cytosolic storage pool and promotion of cytosolic lipid droplets formation (48;49). Microsomal triglyceride transfer protein (MTP) is necessary for the assembly of the nascent lipoprotein particles and insulin negatively regulates MTP expression via activation of the mitogen-activated protein kinase (MAPK) (50), although the time course of insulin regulation of MTP protein suggests that it is unlikely to be the key regulatory site of acute insulin action (51;51). More recently, in vivo and ex vivo studies in the Syrian Golden hamsters have demonstrated that intestinal lipoprotein production in the chow-fed hamsters is responsive to the inhibitory effect of insulin whereas in insulin resistant fructose-fed hamsters intestinal lipoprotein production is refractory to insulin inhibition, suggesting aberrant insulin signaling as an important factor in intestinal lipoprotein particle overproduction in insulin resistant states (26). Qin et al (52) have recently shown that intestinal insulin resistance induced by the proinflammatory cytokine TNF-α is associated with overproduction of intestinally derived lipoproteins in hamsters. TNF-α acts via TNF-α receptors p55 and p75, and the induction of the p38 MAPK pathway could be one of the mechanisms leading to insulin resistance and accompanying intestinal lipoprotein overproduction in those animals. LDL receptor (LDLR) can affect VLDL apoB production through modulation of intracellular apoB degradation (53;54). VLDL apoB production is increased in LDLR-null familial hypercholesterolemia patients (55). Acute administration of insulin upregulates LDLR (56), thus acute insulin may suppress VLDL apoB production through upregulation of LDLR in our study. Future studies examining the effects of acute insulin on VLDL apoB production in LDLR-null patients would yield more direct evidence for this mechanism.

This study has extended previous findings in animal models of insulin resistance to humans and also from the liver to the intestine, demonstrating conclusively that intestinal lipoprotein particle production is inhibited in vivo by acute hyperinsulinaemia. Furthermore, in the present study we have shown that insulin inhibits hepatic apoB100 production acutely in the constant fed state, not only in the fasted state, as has been previously shown (13). Postprandial lipaemia and accumulation of intestinally derived apoB48-containing lipoproteins seen in diabetes is therefore not only due to delayed clearance but also increased production of these particles. In this respect the intestine is regulated in a fashion that is similar to the liver. Even though the absolute production rate of hepatic (apoB100) lipoprotein particles was about 8-fold greater than that of intestinal (apoB48) particles under these experimental conditions, an increase in apoB48 production may contribute to postprandial lipaemia and potentially to atherosclerosis, given that those particles have been shown to be atherogenic (11;30). Future studies in humans are
required to assess whether the acute suppression of intestinal lipoprotein production by insulin is blunted in the insulin resistant state and diabetes, as has been shown recently in the fructose-fed Syrian Golden hamsters (26) and as we (18) and others (20) have previously shown to be the case for hepatic VLDL secretion. If this is indeed shown to be the case, then resistance to insulin’s acute suppressive effect may play an important role in the overproduction of intestinal lipoproteins in insulin-resistant and type 2 diabetic individuals.

In conclusion, the present report provides evidence that intestinal apoB48-containing lipoprotein production in humans is inhibited by acute hyperinsulinemia and that this effect is in part dependant on insulin-mediated suppression of plasma FFAs. This study extends previous observations in animal models to humans and now provides definitive proof that circulating metabolites (FFAs) and hormones (insulin) play an important regulatory role in the secretion of intestinal lipoproteins.

ACKNOWLEDGMENTS
We are indebted to Patricia Harley, RN for her assistance with subject recruitment and conducting the clinical protocol.

Funding sources - This work was supported by funding from the Canadian Institutes for Health Research (MOP-43839). GFL holds a Canada Research Chair in Diabetes and is a Career Investigator of the Heart and Stroke Foundation of Canada. MP is the recipient of a Postdoctoral Fellowship Award from the Banting and Best Diabetes Centre, Canada. BWP was supported by NIH P30 DK56341 (Clinical Nutrition Research Unit).

Disclosures – None
REFERENCES


53. Nassir, F, Xie, Y, Patterson, BW, Luo, J, Davidson, NO: Hepatic secretion of small lipoprotein particles in apobec-1/- mice is regulated by the LDL receptor. *J. Lipid Res.* 45:1649-1659, 2004


LEGEND TO FIGURES

Figure 1. Study protocol (A) and plasma TG (B), FFA (C) and insulin (D) over the time course of the kinetic study. At 4am subjects started to ingest identical hourly, then half hourly volumes of a liquid food supplement. 3 hrs after starting to ingest the formula, an iv infusion with either INS, SAL or INS+IH was started. 3 hrs after starting the iv infusions, a primed, continuous IV infusion of L-[5,5,5-2H3]-leucine was administered for an additional 10 hrs to enrich apoB48 and -B100 (A). Plasma TG (B), FFA (C) and insulin (D) were measured after an overnight fast and then throughout the 10-hr lipoprotein turnover study (0 to 10hr) in subjects receiving Insulin (INS), Saline (SAL) or insulin plus Intralipid and heparin (INS+IH) (n=6). Values are mean ±SEM for each group. The overall significance over the time course of the kinetic study for plasma TG concentration between the three studies was * p<0.0001, for plasma FFA *p<0.0001 with concentrations significantly lower in INS compared with SAL and INS+IH, and no significant difference between INS+IH and SAL. Similarly, Insulin concentration was higher in INS and INS+IH compared with SAL with no significant difference between INS and INS+IH and an overall significance over the time course of the kinetic study between the three groups of *p<0.0001.

Figure 2. Compartmental model of VLDL1 and VLDL2 apoB metabolism. The same structural model was used for both apoB48 and apoB100. Q1 represents plasma deuterated-leucine enrichment; Q4 accounts for isotopic dilution; D2 is an intracellular delay compartment that accounts for synthesis, assembly and secretion of apolipoproteins; Q11 represents VLDL1 lipoprotein output and Q12 is VLDL2 lipoprotein output for apoB48 or apoB100.

Figure 3. Plasma VLDL1 and VLDL2 apoB48 and apoB100 concentrations over the time course of the kinetic study. VLDL1 (A, B) and VLDL2 (C, D) apoB48 (A, C) and B100 (B, D) concentrations were measured after an overnight fast and then throughout the 10-hr lipoprotein turnover study (0-10hr) in the three experimental conditions: Insulin (INS), Saline (SAL) or insulin plus Intralipid and heparin (INS+IH) (n=6). Subjects ingested a liquid fat formula for 16 hrs to achieve a constant fed state. Values are mean ± SEM for each group. The overall significance for both VLDL1 and VLDL2 apoB48 concentrations between the three groups was *p<0.0001 with VLDL1 apoB48 and apoB100 concentrations were significantly lower in INS vs SAL and IH+INS but no significant difference between INS+IH and SAL. Similarly for VLDL2, the overall significance between the three groups for apoB48 and apoB100 were *p=0.036 for apoB48 and *p<0.0001 for apoB100) with concentrations significantly lower in INS vs SAL IH+INS, and no significant difference between INS+IH and SAL.

Figure 4. Effect of insulin infusion on VLDL1 and VLDL2 apoB48 and apoB100 fractional catabolic (FCR) and production rates (PR). VLDL1 and VLDL2 apoB48 and apoB100 FCR and PR were determined in subjects receiving either insulin (INS) (black bars), saline (SAL) (grey bars) or insulin
plus Intralipid and heparin (INS+IH) infusion (white bars). ApoB48 and apoB100 FCR in VLDL1 and VLDL2 did not differ significantly between the three experimental protocols (A - D). VLDL1 apoB48 (E) and apoB100 PR (F) decreased significantly in INS compared to SAL and INS+IH with the overall significance between the three studies *p=0.009 and *p=0.029 respectively. VLDL2 apoB48 PR (G) also decreased significantly with insulin infusion (*p=0.010) while apoB100 PR (H) did not reach significance but showed a strong trend toward reduction (p=0.067). VLDL1 and 2 apoB48 and B100 PR in INS+IH were in all cases intermediate between INS and SAL, but were not significantly different from INS or SAL.

Table 1: Demographic characteristics and fasting biochemical parameters of subjects (n=6).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Mean ± SEM</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>44.7±4.9</td>
<td>21-54</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>78.3±2.6</td>
<td>65.3-81.8</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>24.0±0.8</td>
<td>21.7-25.9</td>
</tr>
<tr>
<td>Glucose (mmol/L)</td>
<td>4.98±0.13</td>
<td>4.4-5.3</td>
</tr>
<tr>
<td>Insulin (pmol/L)</td>
<td>39.7±1.7</td>
<td>27-76.2</td>
</tr>
<tr>
<td>Plasma FFA (mmol/L)</td>
<td>0.40±0.05</td>
<td>0.3-0.6</td>
</tr>
<tr>
<td>Plasma TG (mmol/L)</td>
<td>0.77±0.07</td>
<td>0.5-1.00</td>
</tr>
<tr>
<td>Plasma TC (mmol/L)</td>
<td>3.73±0.22</td>
<td>3.0-4.2</td>
</tr>
<tr>
<td>VLDL1 apoB48 (mg/L)</td>
<td>0.35±0.06</td>
<td>0.13-0.48</td>
</tr>
<tr>
<td>VLDL1 apoB100 (mg/dL)</td>
<td>1.14±0.20</td>
<td>0.8-1.96</td>
</tr>
<tr>
<td>VLDL2 apoB48 (mg/L)</td>
<td>0.66±0.07</td>
<td>0.38-0.82</td>
</tr>
<tr>
<td>VLDL2 apoB100 (mg/dL)</td>
<td>1.22±0.23</td>
<td>0.61-1.92</td>
</tr>
</tbody>
</table>

BMI, body mass index; FFA, free fatty acids; TG, triglycerides; TC, total cholesterol; VLDL, very low density lipoprotein; apoB, apolipoprotein B
Table 2: Mean plasma and VLDL1 and VLDL2 lipids, apoB48 and B100 concentrations, fractional catabolic rates and production rates during the kinetic study in three experimental conditions. Values are mean±SEM for the duration of the 10-hr kinetic study.

<table>
<thead>
<tr>
<th>Variable</th>
<th>INS</th>
<th>SAL</th>
<th>INS+IH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma FFA (mmol/L)</td>
<td>0.12±0.01*</td>
<td>0.25±0.05</td>
<td>0.29±0.03</td>
</tr>
<tr>
<td>Plasma TG (mmol/L)</td>
<td>1.03±0.16*</td>
<td>1.46±0.10</td>
<td>1.91±0.23</td>
</tr>
<tr>
<td>VLDL1 TG (mmol/L)</td>
<td>0.21±0.07*</td>
<td>0.40±0.03</td>
<td>0.50±0.09</td>
</tr>
<tr>
<td>VLDL1 Chol (mmol/L)</td>
<td>0.05±0.02*</td>
<td>0.10±0.01</td>
<td>0.12±0.03</td>
</tr>
<tr>
<td>VLDL1 apoB48 conc. (mg/L)</td>
<td>0.90±0.27*</td>
<td>1.83±0.19</td>
<td>1.63±0.15</td>
</tr>
<tr>
<td>VLDL1 apoB48 FCR (pools/day)</td>
<td>17.6±5.6</td>
<td>12.3±2.4</td>
<td>10.3±1.1</td>
</tr>
<tr>
<td>VLDL1 apoB48 PR (mg.kg⁻¹.day⁻¹)</td>
<td>0.44±0.14*</td>
<td>0.93±0.09</td>
<td>0.73±0.06</td>
</tr>
<tr>
<td>VLDL1 apoB100 conc. (mg/dL)</td>
<td>0.70±0.16*</td>
<td>1.76±0.42</td>
<td>1.97±0.51</td>
</tr>
<tr>
<td>VLDL1 apoB100 FCR (pools/day)</td>
<td>11.8±3.0</td>
<td>11.7±0.9</td>
<td>8.2±1.4</td>
</tr>
<tr>
<td>VLDL1 apoB100 PR (mg.kg⁻¹.day⁻¹)</td>
<td>3.40±0.93*</td>
<td>8.98±2.05</td>
<td>6.09±1.08</td>
</tr>
<tr>
<td>VLDL2 TG (mmol/L)</td>
<td>0.19±0.06*</td>
<td>0.25±0.03</td>
<td>0.36±0.12</td>
</tr>
<tr>
<td>VLDL2 Chol (mmol/L)</td>
<td>0.07±0.02*</td>
<td>0.11±0.02</td>
<td>0.14±0.03</td>
</tr>
<tr>
<td>VLDL2 apoB48 conc. (mg/L)</td>
<td>1.12±0.33*</td>
<td>1.58±0.11</td>
<td>1.56±0.15</td>
</tr>
<tr>
<td>VLDL2 apoB48 FCR (pools/day)</td>
<td>10.2±1.99</td>
<td>12.9±1.5</td>
<td>11.3±1.7</td>
</tr>
<tr>
<td>VLDL2 apoB48 PR (mg.kg⁻¹.day⁻¹)</td>
<td>0.44±0.14*</td>
<td>0.89±0.08</td>
<td>0.75±0.05</td>
</tr>
<tr>
<td>Direct PR</td>
<td>0.00±0.01</td>
<td>-0.03±0.02</td>
<td>0.01±0.02</td>
</tr>
<tr>
<td>PR via VLDL1</td>
<td>0.44±0.14*</td>
<td>0.93±0.09</td>
<td>0.73±0.06</td>
</tr>
<tr>
<td>VLDL2 apoB100 conc. (mg/dL)</td>
<td>0.94±0.31*</td>
<td>1.68±0.58</td>
<td>1.90±0.47</td>
</tr>
<tr>
<td>VLDL2 apoB100 FCR (pools/day)</td>
<td>15.6±4.2</td>
<td>16.7±2.8</td>
<td>11.7±1.7</td>
</tr>
<tr>
<td>VLDL2 apoB100 PR (mg.kg⁻¹.day⁻¹)</td>
<td>5.94±1.69</td>
<td>11.2±2.5</td>
<td>9.07±1.52</td>
</tr>
<tr>
<td>Total PR</td>
<td>2.54±1.36</td>
<td>2.21±0.65</td>
<td>2.98±0.98</td>
</tr>
<tr>
<td>Direct PR</td>
<td>3.40±0.93*</td>
<td>8.98±2.05</td>
<td>6.09±1.08</td>
</tr>
</tbody>
</table>

FFA, free fatty acids; TG, triglyceride; VLDL, very low density lipoprotein; Chol, Cholesterol; apo, apolipoprotein; FCR, fractional catabolic rate; PR, production rate.
* p<0.05 vs SAL.
**Insulin and intestinal lipoprotein secretion**

**Figure 1**

A

<table>
<thead>
<tr>
<th><strong>Saline (65 mL/h)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>OR</td>
</tr>
<tr>
<td><strong>Insulin (40 mU/m².min)</strong></td>
</tr>
<tr>
<td>OR</td>
</tr>
<tr>
<td><strong>Insulin + Intralipid (20%, 15 mL/h) + heparin (250 U/h)</strong></td>
</tr>
</tbody>
</table>

Mixed meal

Shake (hourly)

5pm 4am 7am 10am

D3-leucine

8pm

B

<table>
<thead>
<tr>
<th>Plasma TG (mmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ING</td>
</tr>
<tr>
<td>SAL</td>
</tr>
<tr>
<td>INSH+H</td>
</tr>
</tbody>
</table>

Time (hr)

C

<table>
<thead>
<tr>
<th>Plasma FFA (mmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ING</td>
</tr>
<tr>
<td>SAL</td>
</tr>
<tr>
<td>INSH+H</td>
</tr>
</tbody>
</table>

Time (hr)

D

<table>
<thead>
<tr>
<th>Insulin conc (pmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ING</td>
</tr>
<tr>
<td>SAL</td>
</tr>
<tr>
<td>INSH+H</td>
</tr>
</tbody>
</table>

Time (hr)

**Figure 2**

U (s)

Q1

PAA

k (2,4)

Q4

k (0,11)

U (1)

Q11

apoB/V1

k (0,12)

Q12

apoB/V2

k (12,11)

d(12,2)

d(11,2)

d(2,4)
Insulin and intestinal lipoprotein secretion

Figure 3

A

B

C

D

Figure 4

A

B

C

D

E

F

G

H